PURPOSE: To assess the therapeutic potential of methotrexate (MTX) and 5-[1251]liodo-2'-deoxyuridine (125IdUrd) administered sequentially in rats bearing advanced (ten-day-old) intrathecal (i.t.) TE671 human rhabdomyosarcoma tumours. MATERIALS AND METHODS: Nude rats were injected with TE671 cells through an i.t. placed catheter. Ten days later, the animals were injected i.t. over a 12-day period with (i) saline daily, (ii) MTX every other day, (iii) 125IdUrd every other day, or (iv) MTX and 125IdUrd on alternating days. Onset of paralysis was determined as a function of time, and the medians for onset (M), percentage of cells killed (% kill), and log cell kill were calculated. RESULTS: The data show that (i) injection of MTX leads to a moderate delay in the onset of paralysis (M(MTX) = 29 d versus Msaline = 20 d), (ii) administration of 125IdUrd is more effective (M(IdUrd) = 36 d), and (iii) sequential administration of MTX- 125IdUrd further increases the therapeutic efficacy of 125IdUrd (M(MTX)-IdUrd = 47 d). CONCLUSIONS: Intrathecal injection of MTX-(125)IdUrd is efficacious in the therapy of advanced intrathecal tumours.
PURPOSE: To assess the therapeutic potential of methotrexate (MTX) and 5-[1251]liodo-2'-deoxyuridine (125IdUrd) administered sequentially in rats bearing advanced (ten-day-old) intrathecal (i.t.) TE671 humanrhabdomyosarcoma tumours. MATERIALS AND METHODS: Nude rats were injected with TE671 cells through an i.t. placed catheter. Ten days later, the animals were injected i.t. over a 12-day period with (i) saline daily, (ii) MTX every other day, (iii) 125IdUrd every other day, or (iv) MTX and 125IdUrd on alternating days. Onset of paralysis was determined as a function of time, and the medians for onset (M), percentage of cells killed (% kill), and log cell kill were calculated. RESULTS: The data show that (i) injection of MTX leads to a moderate delay in the onset of paralysis (M(MTX) = 29 d versus Msaline = 20 d), (ii) administration of 125IdUrd is more effective (M(IdUrd) = 36 d), and (iii) sequential administration of MTX- 125IdUrd further increases the therapeutic efficacy of 125IdUrd (M(MTX)-IdUrd = 47 d). CONCLUSIONS: Intrathecal injection of MTX-(125)IdUrd is efficacious in the therapy of advanced intrathecal tumours.
Authors: Rohit Tiwari; Antonio Toppino; Hitesh K Agarwal; Tianyao Huo; Youngjoo Byun; Judith Gallucci; Sherifa Hasabelnaby; Ahmed Khalil; Ayman Goudah; Robert A Baiocchi; Michael V Darby; Rolf F Barth; Werner Tjarks Journal: Inorg Chem Date: 2011-12-16 Impact factor: 5.165
Authors: Elise Verger; Jordan Cheng; Vittorio de Santis; Madeleine Iafrate; Jessica A Jackson; Cinzia Imberti; Gilbert O Fruhwirth; Philip J Blower; Michelle T Ma; Daniel R Burnham; Samantha Y A Terry Journal: Nucl Med Biol Date: 2021-06-15 Impact factor: 2.408
Authors: Hwan Lee; Aladdin Riad; Paul Martorano; Adam Mansfield; Minu Samanta; Vandana Batra; Robert H Mach; John M Maris; Daniel A Pryma; Mehran Makvandi Journal: J Nucl Med Date: 2019-11-01 Impact factor: 11.082